COVID-19 and Lung Cancer Patients | CheckRare
Ross Camidge, MD, PhD of the University of Colorado Cancer Center discusses how the COVID-19 pandemic has influenced rare cancer patients.
Related Articles
Newborn Screening For Lysosomal Disorders
Ozlem Goker-Alpan, MD, Founder and CMO of LDRTC, discusses the importance of newborn screening for lysosomal disorders.
The SUDEP Communication Gap
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Managing Cardiomyopathies in Lysosomal Disorders
Dr Ozlem Goker-Alpan and Dr John Jefferies discuss the role of the cardiologist and best practices for managing Lysosomal Disorders
Gene Therapy for Sickle Cell Disease Likely Cost-Effective at
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.
Marstacimab in Patients with Hemophilia A or B
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.